Asset Details
Do you wish to reserve the book?
A Self‐Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple‐Negative Breast Cancer Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Self‐Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple‐Negative Breast Cancer Therapy
Do you wish to request the book?
A Self‐Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple‐Negative Breast Cancer Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Self‐Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple‐Negative Breast Cancer Therapy
2025
Overview
As a multifunctional extracellular protein, connective tissue growth factor (CTGF/CCN2) is significantly associated with the progression and prognosis of triple‐negative breast cancer (TNBC). However, current blockade therapies targeting CTGF's multiple domains are limited, creating substantial challenges in treatment. Lysosome‐targeting chimeras (LYTACs) have emerged as a promising approach for achieving complete protein degradation and inhibiting CTGF's various bioactivities. In this study, a self‐assembling LYTAC nanoplatform, NanoCLY, designed to tumor microenvironment (TME)‐responsively degrade CTGF is presented. The complete degradation of CTGF downregulates the TGF‐β signaling pathway and disrupts the CTGF‐IL‐6 cell crosstalk within the TME, which further inhibits the activation of inflammatory cancer‐associated fibroblasts (CAFs) and alleviates the inflammatory TME. Notably, the anti‐TNBC effect of LYTAC‐based CTGF degradation therapy surpasses that of antibody‐based blockade therapy in both in vitro and in vivo models. The findings provide a proof of concept for CTGF degradation in TNBC and introduce the first CTGF‐LYTAC nanoplatform aimed at TME‐directed therapy. A CTGF‐LYTAC nanoplatform is developed to selectively degrade connective tissue growth factor (CTGF) in triple‐negative breast cancer (TNBC), inhibiting TGF‐β signaling and cell interactions in the tumor microenvironment (TME). This strategy effectively suppresses tumor growth and metastasis, outperforming antibody‐based therapy. The study provides proof of concept for CTGF degradation and introduces the first CTGF‐LYTAC nanoplatform for TME‐targeted TNBC treatment.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ connective tissue growth factor
/ Connective Tissue Growth Factor - metabolism
/ Design
/ Female
/ Humans
/ Ligands
/ Mice
/ Peptides
/ Proteins
/ self‐assembling nanoparticle
/ Triple Negative Breast Neoplasms - drug therapy
/ Triple Negative Breast Neoplasms - metabolism
/ Triple Negative Breast Neoplasms - pathology
